We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.
- Authors
Tan, E-H; Ramlau, R; Pluzanska, A; Kuo, H-P; Reck, M; Milanowski, J; Au, J S-K; Felip, E; Yang, P-C; Damyanov, D; Orlov, S; Akimov, M; Delmar, P; Essioux, L; Hillenbach, C; Klughammer, B; McLoughlin, P; Baselga, J
- Abstract
Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clinical benefit from erlotinib therapy.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Vol 21, Issue 2, p217
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdp520